Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard W Bruckner

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Anticancer Research|January 2, 2016
Targeted Therapy for Resistant Cholangiocarcinoma with Bevacizumab or Cetuximab Added to Failed Cytotoxic Drug CoresHoward W Bruckner, Azriel Hirschfeld, Myron Schwartz
Anticancer Research|December 27, 2017
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine CancerHoward W Bruckner, Daniel Gurell, Azriel Hirschfeld
Hematology/Oncology Clinics of North America|June 18, 2002
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinomaPeter Kozuch, Magdalena Petryk, Howard W Bruckner
Anticancer Research|August 17, 2005
Bevacizumab as treatment for chemotherapy-resistant pancreatic cancerHoward W Bruckner, Victor R Hrehorovich, Harinder S Sawhney
Frontiers in Molecular Medicine|August 1, 2024
Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breastHoward W Bruckner, Sant P Chawla, Nadezhda Omelchenko, et al.
Plos One|November 2, 2022
Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival timesHoward W Bruckner, Fred Bassali, Elisheva Dusowitz, et al.
Molecular and Clinical Oncology|July 19, 2021
Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature reviewMichael A Morse, Sant P Chawla, Terence Z Wong, et al.
Frontiers in Oncology|July 9, 2024
Cholangiocarcinoma, sequential chemotherapy, and prognostic testsHoward W Bruckner, Robert De Jager, Elisheva Knopf, et al.
Cancer Investigation|October 10, 2003
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreasMiguel Araneo, Howard W Bruckner, Michael L Grossbard, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 17, 2003
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trialsChristian M Kurbacher, Ottilia M Grecu, Ursula Stier, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Anticancer Research|January 2, 2016
Targeted Therapy for Resistant Cholangiocarcinoma with Bevacizumab or Cetuximab Added to Failed Cytotoxic Drug CoresHoward W Bruckner, Azriel Hirschfeld, Myron Schwartz
Anticancer Research|December 27, 2017
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine CancerHoward W Bruckner, Daniel Gurell, Azriel Hirschfeld
Hematology/Oncology Clinics of North America|June 18, 2002
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinomaPeter Kozuch, Magdalena Petryk, Howard W Bruckner
Anticancer Research|August 17, 2005
Bevacizumab as treatment for chemotherapy-resistant pancreatic cancerHoward W Bruckner, Victor R Hrehorovich, Harinder S Sawhney
Frontiers in Molecular Medicine|August 1, 2024
Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breastHoward W Bruckner, Sant P Chawla, Nadezhda Omelchenko, et al.
Plos One|November 2, 2022
Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival timesHoward W Bruckner, Fred Bassali, Elisheva Dusowitz, et al.
Molecular and Clinical Oncology|July 19, 2021
Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature reviewMichael A Morse, Sant P Chawla, Terence Z Wong, et al.
Frontiers in Oncology|July 9, 2024
Cholangiocarcinoma, sequential chemotherapy, and prognostic testsHoward W Bruckner, Robert De Jager, Elisheva Knopf, et al.
Cancer Investigation|October 10, 2003
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreasMiguel Araneo, Howard W Bruckner, Michael L Grossbard, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 17, 2003
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trialsChristian M Kurbacher, Ottilia M Grecu, Ursula Stier, et al.
Pageof 2